Mayne Pharma Group Ltd. is an innovative pharmaceutical company based in Australia, specializing in the commercialization of unique and generic pharmaceuticals. With over 40 years of experience in developing oral drug delivery systems, the company operates through three segments: International, Branded Products (BPD), and Portfolio Products Division (PPD). The International segment focuses on manufacturing and selling branded and generic pharmaceutical products in Australia. The BPD distributes branded women's health products in the US, while the PPD distributes dermatology products in the US. Mayne Pharma Group Ltd. has a medium-risk ESG score of 27.7, reflecting its commitment to environmental sustainability and governance.